.gif "IP Gear")
AICAR
AICA ribonucleotide - Wikipedia, the free encyclopedia
In 2008, researchers at the Salk Institute discovered that AICAR given to experimental mice significantly improves their performance in endurance-type exercise, apparently by converting fast-twitch muscle fibers to the more energy-efficient, fat-burning, slow-twitch type. They also looked at the administration of GW 501516 (also called GW1516) in combination with AICAR. Given to mice that did not exercise, this combination activated 40% of the genes that were turned on when mice were given GW1516 and made to exercise. This suggests it may be possible to obtain some of the benefits of exercising without actually exercising.[4] Because of the enhanced endurance effects, this could potentially be used by athletes to enhance their performance.
GW 501516
GW 501516 - Wikipedia, the free encyclopedia
GW-501,516 (also known as GW1516 or GSK-516) is a drug developed by GlaxoSmithKline, which acts as a PPARδ modulator.[1][2] It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue,[3] and has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation.[4] It has been proposed as a potential treatment for obesity and related conditions,[5] especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies.[6][7]
AICA ribonucleotide - Wikipedia, the free encyclopedia
In 2008, researchers at the Salk Institute discovered that AICAR given to experimental mice significantly improves their performance in endurance-type exercise, apparently by converting fast-twitch muscle fibers to the more energy-efficient, fat-burning, slow-twitch type. They also looked at the administration of GW 501516 (also called GW1516) in combination with AICAR. Given to mice that did not exercise, this combination activated 40% of the genes that were turned on when mice were given GW1516 and made to exercise. This suggests it may be possible to obtain some of the benefits of exercising without actually exercising.[4] Because of the enhanced endurance effects, this could potentially be used by athletes to enhance their performance.
GW 501516
GW 501516 - Wikipedia, the free encyclopedia
GW-501,516 (also known as GW1516 or GSK-516) is a drug developed by GlaxoSmithKline, which acts as a PPARδ modulator.[1][2] It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue,[3] and has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation.[4] It has been proposed as a potential treatment for obesity and related conditions,[5] especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies.[6][7]
